Active Biotech Submits Patent Application Regarding the Mode of Action for Quinoline Compounds

The candidate drugs within the laquinimod, 57-57 and TASQ projects all belong to a chemical group called quinolines. The exact mode of action for quinoline compounds has so far not been defined.

Many immunoregulatory compounds only regulate the immune system quantitatively and are immunosuppressive. The quinolines are immunomodulatory and affect the immune system in a qualitative fashion. Hence, it is pertinent to reveal the mode of action for the quinoline compounds and to define how this is distinct from that of other compounds currently in clinical development.

A first target molecule for the quinolines has now been defined. The molecule demonstrates a structure/activity relationship between the binding of quinoline compounds and their biological activity in an animal model for autoimmune disease.

The defined target molecule is, for example, expressed by a subpopulation of dendritic cells. Dendritic cells have increasingly become a focus of immunology research in being a pivotal cell type in the early activation of the immune response. It is during the interaction between dendritic cells and T lymphocytes that the qualitative characteristics of the immune response are defined.

For further information please contact:

Sven Andréasson,

President & CEO

Tel: +46 46 19 20 00

Email: sven.andreasson@activebiotech.com

Or visit: www.activebiotech.com